AI predicts early onset of sepsis

Researchers from Emory University in Atlanta have developed an artificial intelligence (AI) algorithm capable of predicting the onset of sepsis, according to a study published in Critical Care Medicine.

Researchers hope their algorithm will detect the onset of sepsis—a leading cause of morbidity and mortality—while it can still be treated with antibiotics. In this study, researchers tested the accuracy of the Artificial Intelligence Sepsis Expert algorithm in the prediction of early onset sepsis.

Data was collected from more than 31,000 admissions to Emory University hospital intensive care units as well as 52,000 ICU patients from a public database. After exclusion, data on vital signs and electronic health records from 27,000 patient were used to train the algorithm. In testing the algorithms accuracy, 42,000 patients were evaluated by a set of 65 measures to predict the onset of sepsis within 12, eight, six or four hours.

Results showed the Artificial Intelligence Sepsis Expert achieved predictions at a range of 0.83 to 0.85.

“Using data available in the ICU in real-time, Artificial Intelligence Sepsis Expert can accurately predict the onset of sepsis in an ICU patient 4-12 hours prior to clinical recognition,” concluded first author Shamim Nemati and colleagues. “A prospective study is necessary to determine the clinical utility of the proposed sepsis prediction model.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.